{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-286790","form_type":"8-K","ticker":"CYCN","cik":"0001755237","company_name":"Cyclerion Therapeutics, Inc.","filed_at":"2023-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.321505+00:00","generated_at":"2026-06-07T19:27:30.913687+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cyclerion appoints Michael Higgins and Dina Katabi to Board of Directors; board expands to six members.","bullets":["Board increased to six members; Higgins and Katabi elected effective Nov 30, 2023, both deemed independent under NASDAQ rules.","Higgins appointed Audit Committee Chair; Katabi appointed to Nominating and Corporate Governance Committee.","Higgins is Voyager Therapeutics Chairman and former Ironwood COO; Katabi is MIT professor, MacArthur Fellow, and co-founder of Emerald Innovations.","Compensation: each receives $12,000 cash retainer and 20,000 restricted stock units vesting over 42 months.","Press release signals board refresh to explore possible licenses, mergers, acquisitions, or other investments."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-286790","json":"https://secwatch.observer/filing/0001193125-23-286790.json","markdown":"https://secwatch.observer/filing/0001193125-23-286790.md","text":"https://secwatch.observer/filing/0001193125-23-286790.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1755237/000119312523286790/0001193125-23-286790-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1755237/000119312523286790/d559453d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T19:27:30.913687+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44232c544d","claim":"Michael Higgins was elected as Director at Cyclerion Therapeutics, Inc..","evidence_excerpt":"On November 30, 2023, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) voted to increase the size of the Board of Directors to six (6) directors and also voted to elect each of Michael Higgins and Dina Katabi, Ph.D. to the Board of Directors, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1755237/000119312523286790/0001193125-23-286790-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"66e742224f","claim":"Dina Katabi was elected as Director at Cyclerion Therapeutics, Inc..","evidence_excerpt":"On November 30, 2023, the Board of Directors of Cyclerion Therapeutics, Inc. (the “Company”) voted to increase the size of the Board of Directors to six (6) directors and also voted to elect each of Michael Higgins and Dina Katabi, Ph.D. to the Board of Directors, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1755237/000119312523286790/0001193125-23-286790-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}